| Date |
Time |
Source |
Heading |
|---|
| 5/24/2023 | 09:00 | GLOBE | INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell,.. |
| 5/12/2023 | 08:01 | EDGAR | Current Report Filing (8-k) |
| 5/08/2023 | 08:00 | GLOBE | INmune Bio, Inc. Announces FDA Clearance of IND Application.. |
| 5/04/2023 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 5/03/2023 | 16:10 | GLOBE | INmune Bio Inc. Announces First Quarter 2023 Results and.. |
| 5/03/2023 | 16:02 | EDGAR | Quarterly Report (10-q) |
| 4/24/2023 | 09:00 | GLOBE | INmune Bio, Inc. to Report First Quarter 2023 Financial.. |
| 4/21/2023 | 16:02 | EDGAR | Proxy Statement (definitive) (def 14a) |
| 4/19/2023 | 08:30 | GLOBE | XPro1595 Improves Outcomes in a Mouse Model of TBI-induced.. |
| 4/11/2023 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 4/11/2023 | 08:00 | GLOBE | INmune Bio, Inc. to Present Preclinical Data at the 2023.. |
| 4/03/2023 | 09:13 | EDGAR | Current Report Filing (8-k) |
| 4/03/2023 | 09:00 | GLOBE | INmune Bio, Inc. Announces Submission of Investigational New.. |
| 3/15/2023 | 16:04 | EDGAR | Current Report Filing (8-k) |
| 3/03/2023 | 16:48 | EDGAR | Current Report Filing (8-k) |
| 3/02/2023 | 16:05 | GLOBE | INmune Bio, Inc. Announces 2022 Results and Provides.. |
| 2/22/2023 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 2/22/2023 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 2/21/2023 | 16:10 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 16:08 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 16:07 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 16:05 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 16:04 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 16:03 | EDGAR | Statement of Changes in Beneficial Ownership (4) |
| 2/21/2023 | 09:00 | GLOBE | INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022.. |
| 2/10/2023 | 06:11 | EDGAR | Current Report Filing (8-k) |
| 2/08/2023 | 08:45 | GLOBE | INmune Bio, Inc. Receives Approximately $6.4 Million in.. |
| 1/25/2023 | 09:08 | EDGAR | Current Report Filing (8-k) |
| 1/25/2023 | 07:45 | GLOBE | INmune Bio, Inc. Announces Pre-Clinical Data That Support a.. |
| 12/22/2022 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 12/22/2022 | 08:00 | GLOBE | INmune Bio, Inc., Virginia Commonwealth University, and.. |
| 12/12/2022 | 17:04 | EDGAR | Current Report Filing (8-k) |
| 12/09/2022 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 12/09/2022 | 13:55 | TRMN | Maxim Group Keeps Their Buy Rating on Inmune Bio (INMB) |
| 12/08/2022 | 08:00 | GLOBE | INmune Bio, Inc. Data at ASH Highlight Innovative Natural.. |
| 12/07/2022 | 16:02 | EDGAR | Current Report Filing (8-k) |
| 12/06/2022 | 16:00 | GLOBE | INmune Bio, Inc. Reports Combination Therapy with INB03™.. |
| 11/29/2022 | 08:00 | GLOBE | INmune Bio, Inc. Focused on Novel Clinical Trial Designs to.. |
| 11/14/2022 | 09:00 | GLOBE | INmune Bio, Inc. Receives Health Canada “No Objection.. |
| 11/04/2022 | 16:44 | EDGAR | Current Report Filing (8-k) |
| 11/04/2022 | 10:05 | TRMN | Maxim Group Remains a Buy on Inmune Bio (INMB) |
| 11/02/2022 | 16:00 | GLOBE | INmune Bio, Inc. Announces Third Quarter 2022 Results and.. |
| 10/26/2022 | 08:16 | EDGAR | Current Report Filing (8-k) |
| 10/26/2022 | 08:10 | GLOBE | INmune Bio, Inc. to Report Third Quarter 2022 Financial.. |
| 10/19/2022 | 08:08 | EDGAR | Current Report Filing (8-k) |
| 10/19/2022 | 08:00 | GLOBE | INmune Bio, Inc. Announces Positive Solid Tumor Efficacy.. |
| 9/07/2022 | 16:01 | EDGAR | Current Report Filing (8-k) |
| 9/07/2022 | 09:00 | GLOBE | INmune Bio, Inc. to Present at the H.C. Wainwright 24th.. |
| 8/05/2022 | 08:40 | TRMN | Maxim Group Keeps Their Buy Rating on Inmune Bio (INMB) |
| 8/03/2022 | 16:10 | GLOBE | INmune Bio, Inc. Announces Second Quarter 2022 Results and .. |
